Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy

Erik T. Goluboff, Diane Prager, Daniel Rukstalis, Bruce Giantonio, Martin Madorsky, Israel Barken, I. Bernard Weinstein, Alan W. Partin, Carl A. Olsson, Stuart Holden, Stanley Brosman, Richard Shapiro, Simon Tchekmedyian, Chester Gottlieb, Kyle Himsl

Research output: Contribution to journalArticlepeer-review

66 Scopus citations


Purpose: We evaluated the safety and efficacy of exisulind for delaying disease progression in men with increasing prostate specific antigen (PSA) after radical prostatectomy. Materials and Methods: A total of 96 men with increasing PSA after radical prostatectomy were randomized to receive placebo (49) or 250 mg. exisulind twice daily (47) for 12 months. The primary efficacy parameter was the difference in change from baseline PSA between the placebo and exisulind groups. The PSA doubling time was also evaluated before and during study. A subgroup analysis classified patients based on the risk of developing metastatic disease. Results: Compared with placebo, exisulind significantly suppressed the increase in PSA in all patients (p = 0.017). The results were also statistically significant in men at high risk for metastasis (p = 0.0003) and those who could not be classified according to risk (p = 0.0009). In addition, median PSA doubling time was lengthened in high risk patients on exisulind (2.12 month increase) compared with those on placebo (3.37 month decrease, p = 0.048). Exisulind was well tolerated. Conclusions: Exisulind inhibited the increase in PSA overall and prolonged PSA doubling time in high risk patients compared with placebo. These results suggest that Exisulind has the potential to extend the time from biochemical recurrence to the need for androgen deprivation therapy. Exisulind was well tolerated in this patient population. Our results support further study of Exisulind in the treatment of patients with prostate cancer.

Original languageEnglish (US)
Pages (from-to)882-886
Number of pages5
JournalJournal of Urology
Issue number3
StatePublished - 2001
Externally publishedYes


  • Apoptosis
  • Prostate-specific antigen
  • Prostatectomy
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy'. Together they form a unique fingerprint.

Cite this